Broome Oncology

Bone Cancer News

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Denosumab Active Against Giant Cell Tumor of Bone (February 11, 2010)

In a Phase II clinical trial, denosumab produced high rates of tumor response among patients with recurrent or unresectable giant cell tumors of bone. These results were published in Lancet Oncology. Denosumab is an investigational drug that targets... Continue Reading

Latest Bone Cancer News By Stage


General Bone Cancer

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Denosumab Active Against Giant Cell Tumor of Bone (February 11, 2010)

In a Phase II clinical trial, denosumab produced high rates of tumor response among patients with recurrent or unresectable giant cell tumors of bone. These results were published in Lancet Oncology. Denosumab is an investigational drug that targets... Continue Reading

More General Bone Cancer